A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
This is a phase 3, randomized, double-blind, placebo-control global study. The purpose of
this study is to compare the effect of quizartinib versus placebo (administered with
standard induction and consolidation chemotherapy, then administered as maintenance therapy
for up to 12 cycles) on event-free survival in subjects with FLT3-ITD positive AML.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society